Germany-based genetic tests developer LifeCodexx and the Department of obstetrics of the Charité University Hospital have formed a research alliance to enhance the research and development of a new molecular genetic-based assay designed to detect preeclampsia.
Associated with pregnancy, preeclampsia results in hypertension and proteinuria after the 20th week of gestation. The new assay is expected to detect this disorder early.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Currently, LifeCodexx is also in a research collaboration with the University Hospital Wuerzburg.
The firms have recently finished establishing a clinical proof-of principle that showed the ability of LifeCodexx's quantitative polymerase chain reaction (qPCR) assay to discern patients affected by preeclampsia.
LifeCodexx chief executive officer Dr Michael Lutz said: “We are excited about this new research alliance in the field of preeclampsia, which will continue to establish LifeCodexx at the forefront of providing innovative prenatal care solutions by means of safe and reliable molecular genetic-based tests.
“The positive clinical proof-of-principle for a first assay version based on our qPCR-based technology platform is another key milestone following our recent CE approval for our qPCR-based PrenaTest. Our aim is to launch the novel preeclampsia assay within the coming year.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe new research partnership with Charité is based on the clinical proof-of-principle and will aim at the detection of preeclampsia during the early pregnancy stage.
The new assay is expected to be available in the market during next year.
LifeCodexx develops new and clinically validated non-invasive molecular genetic tests based on molecular analytical methods.
